QTTB
Q32 Bio Inc
$
1.680
- Overview
- Forecast
- Valuation
- Earnings
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
1.8399
Open
1.800
VWAP
1.70
Vol
160.75K
Mkt Cap
--
Low
1.640
Amount
274.00K
EV/EBITDA(TTM)
--
Total Shares
12.20M
EV
-33.02M
EV/OCF(TTM)
--
P/S(TTM)
--
Q32 Bio Inc. is a clinical-stage biotechnology company whose science targets potent regulators of the adaptive immune system to re-balance immunity in autoimmune and inflammatory diseases. It focuses on developing novel biologics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction. Bempikibart (ADX-914), its advanced product candidate, is a fully human anti-interleukin-7 receptor alpha (IL-7Rα), an antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 (IL-7), and thymic stromal lymphopoietin (TSLP). It has completed two Phase IIa clinical trials evaluating bempikibart, SIGNAL-AA for the treatment of alopecia areata (AA), and SIGNAL-AD for the treatment of atopic dermatitis (AD). ADX-097, a Phase 2 asset and the lead product candidate from its complement inhibitor platform, is a humanized anti-C3d monoclonal antibody, fusion protein.
Show More
3 Analyst Rating
792.86% Upside
Wall Street analysts forecast QTTB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for QTTB is 15.00 USD with a low forecast of 10.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
2 Hold
0 Sell
Moderate Buy
792.86% Upside
Current: 1.680
Low
10.00
Averages
15.00
High
20.00
792.86% Upside
Current: 1.680
Low
10.00
Averages
15.00
High
20.00
Wells Fargo
Derek Archila
Hold
Maintains
$16 → $15
2025-03-12
Reason
Wells Fargo
Derek Archila
Price Target
$16 → $15
2025-03-12
Maintains
Hold
Reason
Piper Sandler
Christopher Raymond
Buy
to
Hold
Downgrades
$20 → $4
2025-02-11
Reason
Piper Sandler
Christopher Raymond
Price Target
$20 → $4
2025-02-11
Downgrades
Buy
to
Hold
Reason
Piper Sandler downgraded Q32 Bio to Neutral from Overweight with a price target of $4, down from $20. The firm is surprised by the company's decision to discontinue complement inhibitor ADX-097 before presenting data from the drug's renal basket study. The best course of action is to move to Neutral on the name until a better picture of bempikibart's efficacy profile in alopecia areata emerges, the analyst tells investors in a research note.
BMO Capital
Etzer Darout
Buy
to
Hold
Downgrades
$22 → $3
2025-02-11
Reason
BMO Capital
Etzer Darout
Price Target
$22 → $3
2025-02-11
Downgrades
Buy
to
Hold
Reason
BMO Capital downgraded Q32 Bio to Market Perform from Outperform with a price target of $3, down from $22. The company announced an internal restructuring, discontinuing development of its main value driver, ADX-097, to focus on bempikibart development in patients with alopecia areata, the analyst tells investors in a research note. The firm says that while te decision seems to signal confidence in bempikibart, the drug's early clinical profile is not compelling enough to merit meaningful value beyond what it already assumes. As such, it removed contributions from ADX-097 and downgraded the shares.
BMO Capital
Etzer Darout
Buy
Maintains
$64 → $22
2024-12-12
Reason
BMO Capital
Etzer Darout
Price Target
$64 → $22
2024-12-12
Maintains
Buy
Reason
Guggenheim
Yatin Suneja
Strong Buy
to
Hold
Downgrades
n/a
2024-12-12
Reason
Guggenheim
Yatin Suneja
Price Target
n/a
2024-12-12
Downgrades
Strong Buy
to
Hold
Reason
As previously reported, Guggenheim downgraded Q32 Bio to Neutral from Buy and removed the firm's prior price target following the announcement of "disappointing" topline results from bempikibart's Phase 2 studies in atopic dermatitis and alopecia areata. Though Q32 plans to move forward in AA by enrolling 20 additional patients with a loading dose regimen in the Part B expansion, based on the totality of data, the firm says it has "limited hope" for the applicability of this mechanism of action in AA.
Piper Sandler
Christopher Raymond
Buy
Maintains
$85 → $20
2024-12-11
Reason
Piper Sandler
Christopher Raymond
Price Target
$85 → $20
2024-12-11
Maintains
Buy
Reason
Piper Sandler analyst Christopher Raymond lowered the firm's price target on Q32 Bio to $20 from $85 and keeps an Overweight rating on the shares following messy Phase 2a readouts for bempikibart in both atopic dermatitis and alopecia areata. In Part B of the SIGNAL-AD trial, there was no difference between treatment and placebo on EASI score reduction due to an abnormally high placebo rate, and Q32 Bio is halting all further development activities in this indication. For AA, efficacy data were underwhelming compared to approved JAKi's, and although the company has a plan to try and boost efficacy, Piper thinks the risk here is high and is taking this out of its model for now. This leaves differentiated complement inhibitor ADX-097 as the sole value driver in our model, and the firm looks to preliminary data from the Phase 2 renal basket trial in the first half of 2025 to establish the future value of this name.
See All Ratings
Valuation Metrics
The current forward P/E ratio for Q32 Bio Inc (QTTB.O) is -0.51, compared to its 5-year average forward P/E of -4.29. For a more detailed relative valuation and DCF analysis to assess Q32 Bio Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-4.29
Current PE
-0.51
Overvalued PE
-0.92
Undervalued PE
-7.65
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
Financials
Annual
Quarterly
FY2025Q1
N/A
Total Revenue
FY2025Q1
YoY :
-17.62%
-12.23M
Operating Profit
FY2025Q1
YoY :
-1015.44%
-11.03M
Net Income after Tax
FY2025Q1
YoY :
-85.78%
-0.90
EPS - Diluted
FY2025Q1
YoY :
-14.22%
-12.48M
Free Cash Flow
FY2025Q1
N/A
Gross Profit Margin - %
FY2025Q1
YoY :
-100.00%
N/A
FCF Margin - %
FY2025Q1
N/A
Net Margin - %
FY2025Q1
N/A
ROIC
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
2
555.6K
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
QTTB News & Events
Events Timeline
2025-06-25 (ET)
2025-06-25
07:01:07
Q32 Bio chief medical officer Jason Campagna to depart
2025-06-23 (ET)
2025-06-23
07:36:31
Oxford Biomedica completes acquisition of remaining stake in U.S. subsidiary
2025-04-30 (ET)
2025-04-30
07:09:52
Q32 Bio granted Fast Track designation for bempikibart
Sign Up For More Events
Sign Up For More Events
News
9.5
08-06PRnewswireQ32 Bio Reports Second Quarter 2025 Financial Results and Provides Corporate Update
9.5
07-11BenzingaWhy Levi Strauss Shares Are Trading Higher By 8%; Here Are 20 Stocks Moving Premarket
8.0
07-10NASDAQ.COMNotable Thursday Option Activity: SLNO, OKTA, QTTB
Sign Up For More News
People Also Watch
BIVI
BioVie Inc
1.670
USD
-6.70%
AMPG
Amplitech Group Inc
3.400
USD
+3.34%
OCC
Optical Cable Corp
5.640
USD
+5.03%
EBON
Ebang International Holdings Inc
4.157
USD
+1.12%
AGAE
Allied Gaming & Entertainment Inc
1.560
USD
+1.30%
VYNE
Vyne Therapeutics Inc
0.347
USD
+2.05%
SOND
Sonder Holdings Inc
2.010
USD
+0.50%
QETA
Quetta Acquisition Corp
10.860
USD
0.00%
LTRN
Lantern Pharma Inc
4.450
USD
+2.77%
TURN
180 Degree Capital Corp
4.313
USD
-1.30%
FAQ
What is Q32 Bio Inc (QTTB) stock price today?
The current price of QTTB is 1.68 USD — it has decreased -6.15 % in the last trading day.
What is Q32 Bio Inc (QTTB)'s business?
What is the price predicton of QTTB Stock?
What is Q32 Bio Inc (QTTB)'s revenue for the last quarter?
What is Q32 Bio Inc (QTTB)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Q32 Bio Inc (QTTB)'s fundamentals?
How many employees does Q32 Bio Inc (QTTB). have?